Sugi Predict

Sugi Predict / Compounds / SCHEMBL1711567

SCHEMBL1711567

SCHEMBL1711567

CC1CC(c2ccncc2[N+](=O)[O-])=CC(NC(=O)O)C1O

nearest known ligand 0.35

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.34
▸ HTT P42858 5/20 0.32
▸ GAA P10253 2/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ NCOA1 Q15788 1/20 0.31
▸ NCOA3 Q9Y6Q9 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ MAPT P10636 3/20 0.31
▸ NPC1 O15118 1/20 0.30
▸ LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1711565 1.00 KMT2A (0.35) KMT2AMEN1ALDH1A1HTTGAA
SCHEMBL16698753 1.00 KMT2A (0.35) KMT2AMEN1ALDH1A1HTTGAA
SCHEMBL16698755 1.00 KMT2A (0.35) KMT2AMEN1ALDH1A1HTTGAA
SCHEMBL15588770 0.88 BRS3 (0.33) KMT2AMEN1ALDH1A1HTTGAA
SCHEMBL15589037 0.88 BRS3 (0.33) KMT2AMEN1ALDH1A1HTTGAA
SCHEMBL9607182 0.88 BRS3 (0.33) KMT2AMEN1ALDH1A1HTTGAA
SCHEMBL4127006 0.88 BRS3 (0.33) KMT2AMEN1ALDH1A1HTTGAA
SCHEMBL1725546 0.88 BRS3 (0.33) KMT2AMEN1ALDH1A1HTTGAA
SCHEMBL9607188 0.83 KMT2A (0.37) KMT2AMEN1ALDH1A1HTTGAA
SCHEMBL9607187 0.83 KMT2A (0.37) KMT2AMEN1ALDH1A1HTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2861585-B1 NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2019-01-09 — — EP disclosed
US-20150336960-A1 ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS NOVARTIS AG (CH) 2015-11-26 — — US disclosed
US-20150315150-A1 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2015-11-05 — — US disclosed
US-9173883-B2 Ring-substituted N-pyridinyl amides as kinase inhibitors NOVARTIS AG (CH) 2015-11-03 — — US disclosed
EP-2935270-A1 ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS Novartis AG (CH) 2015-10-28 — — EP disclosed
EP-2344474-B1 PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS NOVARTIS AG (CH) 2015-09-23 — — EP disclosed
US-9079889-B2 Kinase inhibitors and methods of their use NOVARTIS AG (CH) 2015-07-14 — — US disclosed
US-20150150873-A1 NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2015-06-04 — — US disclosed
US-20150133473-A1 NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2015-05-14 — — US disclosed
EP-2861585-A1 NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS Novartis AG (CH) 2015-04-22 — — EP disclosed
WO-2012120428-A1 NOVEL KINASE INHIBITORS NOVARTIS AG (CH) 2012-09-13 — — WO disclosed
US-20120225062-A1 NOVEL KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2012-09-06 — — US disclosed
US-20120202851-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2012-08-09 — — US disclosed
US-20120134987-A1 KINASE INHIBITORS AND METHODS OF THEIR USE BURGER MATTHEW T (US) 2012-05-31 — — US disclosed
US-8168794-B2 Pim kinase inhibitors and methods of their use NOVARTIS AG (CH) 2012-05-01 — — US disclosed
EP-2344474-A1 PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS Novartis AG (CH) 2011-07-20 — — EP disclosed
EP-2262802-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE Novartis AG (CH) 2010-12-22 — — EP disclosed
WO-2010026124-A1 PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS NOVARTIS AG (CH) 2010-03-11 — — WO disclosed
US-20100056576-A1 Kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-03-04 — — US disclosed
WO-2009109576-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2009-09-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150133473-A1 NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS PIM1, PIM2, MAP3K1 KMT2A 1870/4885MEN1 3678/4885ALDH1A1 1348/4885
US-20120134987-A1 KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 KMT2A 655/4885MEN1 2942/4885ALDH1A1 2467/4885
US-20100056576-A1 Kinase inhibitors and methods of their use PIM1, PIM2, PIM3 KMT2A 655/4885MEN1 2942/4885ALDH1A1 2467/4885
US-20120225062-A1 NOVEL KINASE INHIBITORS PIM1, PIM2, PIM3 KMT2A 966/4885MEN1 2222/4885ALDH1A1 1758/4885
US-20150315150-A1 KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 KMT2A 655/4885MEN1 2942/4885ALDH1A1 2467/4885
US-20150150873-A1 NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS PIM1, PIM2, MAP3K1 KMT2A 1870/4885MEN1 3678/4885ALDH1A1 1348/4885
US-20120202851-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 KMT2A 1446/4885MEN1 3664/4885ALDH1A1 1386/4885
US-20150336960-A1 ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS PIM1, PIM2, PIM3 KMT2A 2907/4885MEN1 4161/4885ALDH1A1 1111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.